Blog

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Photo of Zhen Su

Sep 14, 2024, 12:01

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn:

“Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1 Bispecific) from Akeso Inc. vs. Pembrolizumab (Anti PD-1) topline results are out at WCLC. PFS HR: 0.51 H2H and benefits observed across all major subgroups. Congratulations to AKESOBIO team! Really excited to see the next-gen IO reagents (bispecific IO) continue to push the boundaries higher for better patient care.

Still more to learn why it worked so well. But for the NSCLC patients who were enrolled in the investigational arm… doubling progress free survival is what matters!”

Source: Zhen Su/LinkedIn

Akeso Inc. Anti-PD-1 anti-VEGF bispecific IO cancer ivonescimab Marengo Therapeutics next-gen IO reagents NSCLC OncoDaily Oncology pembrolizumab Phase III trial WCLC 2024 Zhen Su

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage